Global ST2 Biomarker Market Growth (Status and Outlook) 2023-2029

Global ST2 Biomarker Market Growth (Status and Outlook) 2023-2029

Cardiac biomarkers are the substances that are released into the bloodstream when the heart is stressed or damaged. Suppression of tumorigenicity 2 (ST2) is one such biomarker used to help in measurement of heart failure risk to assess the treatment options. The ST2 biomarker is a member of the interleukin-1 receptor family biomarker. It is a strong predictor and most promising biomarker for both chronic and acute heart failure.

LPI (LP Information)' newest research report, the “ST2 Biomarker Industry Forecast” looks at past sales and reviews total world ST2 Biomarker sales in 2022, providing a comprehensive analysis by region and market sector of projected ST2 Biomarker sales for 2023 through 2029. With ST2 Biomarker sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world ST2 Biomarker industry.

This Insight Report provides a comprehensive analysis of the global ST2 Biomarker landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on ST2 Biomarker portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global ST2 Biomarker market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for ST2 Biomarker and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global ST2 Biomarker.

The global ST2 Biomarker market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for ST2 Biomarker is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for ST2 Biomarker is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for ST2 Biomarker is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key ST2 Biomarker players cover Thermo Fisher Scientific, BD, Roche, Abbott, Siemens, Bio-Rad and BioMerieux, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of ST2 Biomarker market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
ELISA Based ST2 Biomarker
Immunochromatography Based ST2 Biomarker

Segmentation by application
Hospitals
Diagnostic Centres
Ambulatory Surgical Centres
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Thermo Fisher Scientific
BD
Roche
Abbott
Siemens
Bio-Rad
BioMerieux

Please note: The report will take approximately 2 business days to prepare and deliver.